PLYMOUTH
MEETING, Pa., Feb. 21,
2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a
biotechnology company focused on developing and commercializing DNA
medicines to help treat and protect people from HPV-associated
diseases, cancer, and infectious diseases, today announced that
fourth quarter and year-end 2023 financial results will be released
after the market close on March 6,
2024. Following the release, INOVIO will host a live
conference call and webcast at 4:30 p.m.
ET to discuss financial results and provide a general
business update.
The live webcast will be available online at
http://ir.inovio.com/events-and-presentations/default.aspx. This is
a listen-only event but will include a live Q&A with analysts.
The webcast will be archived and available for replay for 90 days
following the event.
About INOVIO
INOVIO is a biotechnology company focused
on developing and commercializing DNA medicines to help treat and
protect people from HPV-related diseases, cancer, and infectious
diseases. INOVIO's technology optimizes the design and delivery of
innovative DNA medicines that teach the body to manufacture its own
disease-fighting tools. For more information, visit
www.inovio.com.
Contacts
Media: Jennie
Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267)
440-4298 thomas.hong@inovio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-fourth-quarter-and-year-end-2023-financial-results-on-march-6-2024-302066820.html
SOURCE INOVIO Pharmaceuticals, Inc.